Crossmark

Decreasing incidence of pharmacologically and non-pharmacologically treated type 2 diabetes in Norway: a nationwide study

Crossref DOI link: https://doi.org/10.1007/s00125-018-4681-4

Published Online: 2018-07-11

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ruiz, Paz L. D. https://orcid.org/0000-0002-3404-2060
Stene, Lars C.

Bakken, Inger J.

Håberg, Siri E.

Birkeland, Kåre I.

Gulseth, Hanne L.
Funding

Funding for this research was provided by:

South-Eastern Norway Regional Health Authority

Norwegian Institutet of Public Health

Research Council of Norway (262700)
License Information

Text and Data Mining valid from 2018-07-11
More Information

Article History

Received: 24 March 2018

Accepted: 6 June 2018

First Online: 11 July 2018

Duality of interest

: KIB has received grants to his institution for lecturing and consulting from AstraZeneca, Novo Nordisk, Sanofi, Lilly, Boehringer Ingelheim and Merck Sharp & Dohme. HLG has received grants for lectures or consulting from AstraZeneca, Novo Nordisk, Sanofi, Boehringer Ingelheim and Merck Sharp & Dohme. Other authors do not have any conflicts of interest.